Simvastatin
- Generic Name
- Simvastatin
- Brand Names
- Cholib, FloLipid, Simcor, Vytorin, Zocor
- Drug Type
- Small Molecule
- Chemical Formula
- C25H38O5
- CAS Number
- 79902-63-9
- Unique Ingredient Identifier
- AGG2FN16EV
- Background
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liv...
- Indication
Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
...
- Associated Conditions
- Cardiovascular Events, Diabetes Mellitus, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Mixed Hyperlipidemia, History of coronary heart disease cardiovascular event, History of stroke or other cerebrovascular disease cardiovascular event
- Associated Therapies
- -
A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2005-12-07
- Lead Sponsor
- Alabama Neurology Associates, PC
- Target Recruit Count
- 30
- Registration Number
- NCT00242268
- Locations
- 🇺🇸
Alabama Neurology Associates, Birmingham, Alabama, United States
A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT00235963
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 18144
- Registration Number
- NCT00202878
Simvastatin as a Treatment for Pulmonary Hypertension
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 42
- Registration Number
- NCT00180713
- Locations
- 🇩🇪
Department of Internal Medicine II, Klinikstrasse 36 D-35392, Gießen, Germany
🇬🇧Hammersmith Hospital, Du Cane Road, London, United Kingdom
🇬🇧Royal Brompton Hospital, Sydney Street, London, United Kingdom
Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 45
- Registration Number
- NCT00185107
- Locations
- 🇺🇸
Medical Office, Statesville, North Carolina, United States
🇺🇸Scripps Clinic, San Diego, California, United States
🇺🇸Linder Clinical Trial Center, Cincinnati, Ohio, United States
EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 367
- Registration Number
- NCT00166530
Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8600
- Registration Number
- NCT00159835
- Locations
Pfizer Investigational Site
Ezetimibe and Simvastatin in Dyslipidemia of Diabetes
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-02-13
- Target Recruit Count
- 108
- Registration Number
- NCT00157482
- Locations
- 🇮🇹
Hospital "Ospedali Riuniti di Bergamo" - Diabetologic Unit, Bergamo, Italy
🇮🇹Hospital "Treviglio Caravaggio " - Diabetologic Unit, Treviglio, Bergamo, Italy
🇮🇹Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy
Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2021-02-18
- Target Recruit Count
- 383
- Registration Number
- NCT00141141
- Locations
- 🇮🇹
Pfizer Investigational Site, Udine, Italy
Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)
- Conditions
- Interventions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 248
- Registration Number
- NCT00129402
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.